Brought to you by 
Amgen partners with Cytokinetics on heart failure drug
Jan 2007
Executive Summary
Amgen has teamed up with Cytokinetics (developing small-molecule therapeutics that focus on the cytoskeleton) to discover, develop, and market small-molecule heart failure pharmaceuticals globally, excluding Japan. The companies will create compounds that activate cardiac muscle contractility.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Intra-Biotech Deal
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen partners with Cytokinetics on heart failure drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice